Organization | University of Bonn

University of Bonn Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Bonn Germany (1818)

Organization Overview

First Clinical Trial

1996

NCT01057654

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Bonn University | Bonn University, Germany | Children`s Medical Hospital, University of Bonn, Germany | Department of Dermatology and Allergy, University of Bonn | Department of Dermatology University of Bonn | Department of Neurology University Hospital Bonn | Department of Psychiatry and Psychotherapy University Bonn, Clinical Centre | Department of Psychiatry University of Bonn | Department of Psychiatry, University of Bonn, Germany | Department of Psychology, University of Bonn | Dermatologisches Zentrum Bonn | Deutsche Forschungsgemeinschaft, Bonn, Germany | Division of Neurooncology, Departement of Neurology, University Hospital Bonn | Medical Clinic & Policlinic III, University Hospital Bonn | Medical Department I, University Hospital, Bonn University | Medical Department I, University Hospital, Bonn University, Germany | MVZ - Dermatologisches Zentrum Bonn GmbH | Neurologische Universitaetsklinik Bonn | Neurooncology, University Hospital Bonn | PD Dr. Marcus Müller | PD Dr. Martin Glas | Pediatric Hematology/Oncology, University Children's Hospital, Bonn, Germany | Universitaets Augenklinik Bonn | Universitaetsklinik Bonn | Universitaetsklinikum Bonn | Universitatsklinikum Bonn | Universitatsklinikum Bonn, Klinik fur Epileptologie | University Bonn | University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn) | University Clinic Bonn | University Hospital, Bonn | University Hospital Bonn, Bonn, Germany | University hospital of Bonn, Department of Internal Medicine II, Bonn, Germany | University Hospital of Bonn, Germany | University of Bonn | University of Bonn, Clinic for Psychiatry and Psychotherapy | University of Bonn, Department of Ophthalmology | University of Bonn, Department of Psychiatry | University of Bonn Medical Faculty

Active Ingredients

Drugs in Phase 4 Trials (16)

acamprosate (campral) (1 trial)

albumin (Human) (Plasbumin) (1 trial)

amisulpride (1 trial)

atazanavir (reyataz) (1 trial)

azithromycin (zithromax) (1 trial)

dabigatran (pradaxa) (1 trial)

galantamine (reminyl) (2 trials)

haloperidol (haldol) (2 trials)

interferon alpha-2b (Intron-A) (2 trials)

lorazepam (ativan) (2 trials)

memantine (namenda) (2 trials)

raltegravir (isentress) (1 trial)

ranibizumab (lucentis) (6 trials)

risperidone (risperdal) (1 trial)

ritonavir (Norvir) (1 trial)

zonisamide (Zonegran) (1 trial)

Drugs in Phase 3 Trials (43)

ameluz (1 trial)

aminolevulinic acid (levulan) (1 trial)

antihemophilic factor viii human (Hemofil M) (1 trial)

autologous mononuclear stem cell (1 trial)

bivalirudin (angiomax) (1 trial)

bromocriptine (parlodel) (1 trial)

bupropion (wellbutrin) (1 trial)

calcipotriene (dovonex) (1 trial)

carboplatin (paraplatin) (2 trials)

ciprofloxacin (cipro) (1 trial)

cisplatin (platinol) (1 trial)

dexamethasone (1 trial)

diclofenac (voltaren) (1 trial)

doxorubicin (Doxil) (1 trial)

emtricitabine (emtriva) (1 trial)

escitalopram (lexapro) (1 trial)

etoposide (vepesid) (2 trials)

fentanyl (Innovar) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

heparin (liquaemin) (1 trial)

immune globulin (human) (1 trial)

irinotecan (Camptosar) (1 trial)

lenalidomide (revlimid) (1 trial)

lifibrol (1 trial)

lomustine (2 trials)

mesalamine (rowasa) (1 trial)

morphine (1 trial)

nimotuzumab (2 trials)

oxaliplatin (eloxatin) (1 trial)

phenprocoumon (liquamar) (1 trial)

pravastatin (pravachol) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

ribavirin (virazole) (1 trial)

sorafenib (nexavar) (1 trial)

tacrolimus (prograf) (1 trial)

temozolomide (temodar) (4 trials)

tenofovir (viread) (1 trial)

thiotepa (1 trial)

trophosphamide (1 trial)

urea (2 trials)

vincristine (oncovin) (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (12)

aflibercept (zaltrap) (1 trial)

albuterol (proventil) (1 trial)

azd7594 (1 trial)

bortezomib (velcade) (1 trial)

bosutinib (bosulif) (1 trial)

cladribine (leustatin) (1 trial)

dasatinib (sprycel) (1 trial)

doxycycline (vibramycin) (1 trial)

idarubicin (idamycin) (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

s42909 (1 trial)

thalidomide (Thalomid) (1 trial)

Drugs in Phase 1 Trials (7)

cytarabine (cytosar-u) (1 trial)

dovitinib (1 trial)

estradiol (progynon depot) (1 trial)

interferon beta-1b (betaseron) (1 trial)

oxytocin (syntocinon) (14 trials)

sunitinib (sutent) (1 trial)

vorinostat (zolinza) (1 trial)

Drugs in Other Trials (12)

adenosine (Adenocard) (1 trial)

glutaminol (1 trial)

ketamine (ketalar) (1 trial)

lithium (lithonate) (1 trial)

nicotine (nicorette) (1 trial)

pimecrolimus (elidel) (1 trial)

poractant alfa (curosurf) (1 trial)

remifentanil (ultiva) (1 trial)

risedronate (actonel) (1 trial)

simvastatin (zocor) (1 trial)

sodium chloride (1 trial)

xanthohumol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acanthocheilonemiasis (Phase 2)

Alcoholism (Phase 4)

Alzheimer Disease (Phase 4)

Aortic Valve Stenosis (Phase 3)

Asthma (Phase 2)

Astrocytoma (Phase 3)

Atrial Fibrillation (Phase 4)

Bacterial Infections (Phase 4)

Blepharospasm (Phase 2)

Brain Neoplasms (Phase 3)

Buruli Ulcer (Phase 2)

Cancer Pain (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Cholangitis (Phase 4)

Choroidal Neovascularization (Phase 2)

Coinfection (Phase 2)

Communicable Diseases (Phase 4)

Cystic Fibrosis (Phase 4)

Dementia (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Dipetalonema Infections (Phase 2)

Dissociative Disorders (Phase 4)

Encephalitis (Phase 3)

Ependymoma (Phase 3)

Epilepsy (Phase 4)

Fever (Phase 3)

Fibrosis (Phase 4)

Glioblastoma (Phase 3)

Hemophilia A (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

Hepatitis C (Phase 4)

Hepatitis, Chronic (Phase 3)

Hepatoblastoma (Phase 3)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Hyperprolactinemia (Phase 3)

Infections (Phase 4)

Inflammation (Phase 3)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Leg Ulcer (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Liver Diseases (Phase 4)

Macular Degeneration (Phase 3)

Macular Edema (Phase 4)

Mansonelliasis (Phase 2)

Medulloblastoma (Phase 3)

Melanoma (Phase 1)

Meningeal Carcinomatosis (Phase 1)

Mental Disorders (Phase 4)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms, Plasma Cell (Phase 3)

Neovascularization, Pathologic (Phase 2)

Neutropenia (Phase 3)

Oligodendroglioma (Phase 3)

Pneumonia (Phase 4)

Prodromal Symptoms (Phase 4)

Pseudoxanthoma Elasticum (Phase 2)

Psoriasis (Phase 3)

Psychotic Disorders (Phase 4)

Recurrence (Phase 1)

Retinal Detachment (Phase 4)

Retinal Vein Occlusion (Phase 4)

Schizophrenia (Phase 4)

Sclerosis (Phase 1)

Seizures (Phase 4)

Telangiectasis (Phase 2)

Thromboembolism (Phase 4)

Thrombosis (Phase 3)

Tuberculosis (Phase 2)

Ulcer (Phase 2)

Urinary Tract Infections (Phase 4)

Varicose Ulcer (Phase 2)

Venous Thromboembolism (Phase 3)

Venous Thrombosis (Phase 3)

Wounds and Injuries (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 81
# of Trial APIs: 90